Works Cited

1. Periman S. Another decade, another coronavirus. N Engl J Med. 2020;382:760-762.

2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.

3. Centers for Disease Control and Prevention. Coronavirus: Resources and References. Available at https://www.cdc.gov/coronavirus/resources.html. Last accessed October 28, 2020.

4. Munster VJ, Koopmans M, van Doremalen N, et al. A novel coronavirus emerging in China: key questions for impact assessment. N Engl J Med. 2020;382:692-694.

5. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS Coronavirus. N Engl J Med. 2014;370:2499-2505.

6. Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-Coronavirus in household contacts. N Engl J Med. 2014;371:828-835.

7. Assiri A, McGeer A, Peri TM, et al. Hospital outbreak of Middle East Respiratory Syndrome Coronavirus. N Engl J Med. 2013;369:407-416.

8. World Health Organization. Coronavirus Disease (COVID-19) Pandemic. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Last accessed January 5, 2021.

9. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

10. Infectious Disease Society of America. COVID-19 Resource Center. Available at https://www.idsociety.org/covid-19-real-time-learning-network. Last accessed October 28, 2020.

11. World Health Organization. Coronavirus Disease (COVID-19) Advice for the Public. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Last accessed October 28, 2020.

12. Centers for Disease Control and Prevention. Coronavirus Disease (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/index.html. Last accessed January 5, 2021.

13. Centers for Disease Control and Prevention. Travel During the COVID-19 Pandemic. Available at https://www.cdc.gov/coronavirus/2019-ncov/travelers/travel-during-covid19.html. Last accessed October 28, 2020.

14. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Last accessed October 28, 2020.

15. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html Last accessed October 28, 2020.

16. U.S. Food and Drug Administration. FDA Takes Significant Step in Coronavirus Response Efforts, Issues Emergency Use Authorization for the First 2019 Novel Coronavirus Diagnostic. Available at https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first. Last accessed October 28, 2020.

17. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.

18. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.

19. van Doremalen N, Bushmaker T, Morris DH, et al. To the editor: aerosolized and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-1567.

20. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382:1787-1799.

21. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-739.

22. Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938.

23. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.

24. Centers for Disease Control and Prevention. How to Protect Yourself and Others. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html. Last accessed October 28, 2020.

25. Centers for Disease Control and Prevention. Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html. Last accessed October 28, 2020.

26. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327-2336.

27. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-1589.

28. U.S. Food and Drug Administration. Donate COVID-19 Plasma. Available at https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma. Last accessed October 28, 2020.

29. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Blood Purification Device to Treat COVID-19. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-blood-purification-device-treat-covid-19. Last accessed October 28, 2020.

30. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.

31. Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:590-592.

32. Pei G, Zhang Z, Peng J, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Neph. 2020;31(6):1157-1165.

33. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.

34. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020;141:1648-1655.

35. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19: final report. N Engl J Med. 2020; [Epub ahead of print].

36. U.S. Food and Drug Administration. Emergency Use Authorization for Use of Chloroquine Phosphate or Hydroxychloroquine Sulphate for Treatment of 2019 Coronavirus Disease. Available at https://www.fda.gov/media/136534/download. Last accessed October 28, 2020.

37. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382:2411-2418.

38. Gandhi M, Yokie DS, Havlir DV. Asymptomatic transmission, the Achilles' heel of current strategies to control Covid-19. N Engl J Med. 2020;382:2158-2160.

39. Cannegieter S, Klok FA. COVID-19-associated coagulopathy and thromboembolic disease: commentary on an interim expert guidance. Res Pract Thromb Haemost. 2020;4(4):439-445.

40. COVID-19 coagulopathy: an evolving story. Lancet. 2020;7(6):E425.

41. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.

42. Helms J, Tacquard C, Severac F, et al. for the CRICS TRIGGERSEP Group. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.

43. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020;191:145-147.

44. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med. 2020;382:2372-2374.

45. Centers for Disease Control and Prevention. Information for Pediatric Healthcare Providers. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html. Last accessed October 28, 2020.

46. New York State Department of Health. Childhood Inflammatory Disease Related to COVID-19. Available at https://coronavirus.health.ny.gov/childhood-inflammatory-disease-related-covid-19. Last accessed October 28, 2020.

47. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):P1607-P1608.

48. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational study. Lancet. 2020;395(10239):P1771-P1778.

49. Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Available at https://www.cdc.gov/mis-c/hcp. Last accessed October 28, 2020.

50. Qui H, Wu J, Hang L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational study. Lancet. 2020;20(6):P689-P696.

51. Gudbjartsson D, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382:2302-2315.

52. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020;71(15):825-832.

53. Bunvavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427-2429.

54. Centers for Disease Control and Prevention. Considerations for Wearing Masks. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html. Last accessed October 28, 2020.

55. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR. 2020;69(24):759-765.

56. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med. 2020;383:989-992.

57. National Institutes of Health. COVID-19 Treatment Guidelines: Therapeutic Management of Patients with COVID-19. Available at https://www.covid19treatmentguidelines.nih.gov/therapeutic-management. Last accessed October 28, 2020.

58. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and-hydroxychloroquine. Last accessed October 28, 2020.

59. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Health Departments, Appendices. Available at https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html. Last accessed October 28, 2020.

60. Burke RM, Killerby ME, Newton S, et al. Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020. MMWR. 2020;69:904-908.

61. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334-346.

62. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383:347-358.

63. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020; [Epub ahead of print].

64. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020; [Epub ahead of print].

65. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet. 2020;396(10249):P467-P478.

66. Brooks JT, Butler JC, Redfield RR. Universal masking to prevent SARS-CoV-2 transmission—the time is now. JAMA. 2020;324(7):635-637.

67. Hendrix MJ, Wade C, Findley K, Trotman R. Absence of transmission of SARS-CoV-2 after exposure at a hair salon with universal face mask policy—Springfield, Missouri. MMWR. 2020;69(28):930-932.

68. Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603-605.

69. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. MMWR. 2020;69:993-998.

70. Cavalcanti AB, Zampieri FG, Rosa RC, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020; [Epub ahead of print].

71. Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-center, randomized, controlled trial. Available at https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1. Last accessed October 28, 2020.

72. National Institutes of Health. NIH Halts Clinical Trial of Hydroxychloroquine. Available at https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine. Last accessed October 28, 2020.

73. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients. Available at https://www.fda.gov/media/141478/download. Last accessed October 28, 2020.

74. Biran N, Andrew I, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicenter observational study. Lancet Rheumatology. 2020;2(10):e603-e612.

75. Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: a potential strategy to avoid steroid-related Strongyloides hyperinfection. JAMA. 2020;324(7):623-624.

76. Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. Available at https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1. Last accessed October 28, 2020.

77. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care system. Ann Int Med. 2020; [Epub ahead of print].

78. Kass DA. COVID-19 and obesity: a big problem? Ann Int Med. 2020; [Epub ahead of print].

79. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Last accessed October 28, 2020.

80. U. S. Food and Drug Administration. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization for Medical Devices: In Vitro Diagnostics EUAs. Available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-antigen. Last accessed October 28, 2020.

81. Fournier J, Casanovas-Massana A, Campbell M, et al. To the editor: Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020;383:1283-1286.

82. Hanson KE, Barker AP, Hillyard DR, et al. Self-collected anterior nasal and salivary specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. J Clin Microbiol. 2020; [Epub ahead of print].

83. Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing. Available at https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html. Last accessed October 28, 2020.

84. U.S. Food and Drug Administration. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization for Medical Devices: EUA Authorized Serology Test Performance. Available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. Last accessed October 28, 2020.

85. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324:131-132.

86. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020; [Epub ahead of print].

87. Chu DK, Aki EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systemic review and meta-analysis. Lancet. 2020;395:1973-1987.

88. Centers for Disease Control and Prevention. Duration of Isolation and Precautions for Adults with COVID-19. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Last accessed October 28, 2020.

89. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions: COVID-19 Risk. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html#COVID-19-Risk. Last accessed October 28, 2020.

90. U.S. Food and Drug Administration. FDA Approves First Treatment for COVID-19. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Last accessed October 28, 2020.

91. Parr JB. Time to reassess tocilizumab's role in COVID-19 pneumonia. JAMA Intern Med. 2020; [Epub ahead of print].

92. Pringle JC, Leikauskas J, Ransom-Kelly S, et al. COVID-19 in a correctional facility employee following multiple brief exposures to persons with COVID-19—Vermont, July–August 2020. MMWR. 2020; [Epub ahead of print].

93. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2020; [Epub ahead of print].

94. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2020; [Epub ahead of print].

95. U.S. Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab. Available at https://www.fda.gov/media/143603/download. Last accessed January 5, 2021.

96. U.S. Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. Available at https://www.fda.gov/media/143892/download. Last accessed January 5, 2021.

97. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; [Epub ahead of print].

98. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; [Epub ahead of print].

99. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020; [Epub ahead of print].

100. Dooling K, Marin M, Wallace M, et. al. The Advisory Committee on Immunization Practices’ updated interim recommendation for allocation of COVID-19 vaccine—United States, December 2020. MMWR. 2021;69:1657-660.

101. Centers for Disease Control and Prevention. COVID-19 Vaccination: Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. Available at https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Last accessed January 5, 2021.

102. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2020; [Epub ahead of print].

103. Centers for Disease Control and Prevention. COVID-19 Vaccination, Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. Available at https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html. Last accessed January 5, 2021.

104. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2. Available at https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html. Last accessed January 5, 2021.



Privacy Policy
Copyright © 2020 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.